2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-[(2R,4R)-4-hydroxy-6-methyl-5-oxo-3-[(2S,4S,5R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]chromen-4-one
Internal ID | e4738136-e8d2-4f36-89b2-84e75a664500 |
Taxonomy | Phenylpropanoids and polyketides > Flavonoids > Flavonoid glycosides > Flavonoid C-glycosides |
IUPAC Name | 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-[(2R,4R)-4-hydroxy-6-methyl-5-oxo-3-[(2S,4S,5R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]chromen-4-one |
SMILES (Canonical) | CC1C(C(C(C(O1)OC2C(C(=O)C(OC2C3=C(C4=C(C=C3O)OC(=CC4=O)C5=CC(=C(C=C5)O)O)O)C)O)O)O)O |
SMILES (Isomeric) | CC1[C@@H]([C@@H](C([C@@H](O1)OC2[C@H](C(=O)C(O[C@@H]2C3=C(C4=C(C=C3O)OC(=CC4=O)C5=CC(=C(C=C5)O)O)O)C)O)O)O)O |
InChI | InChI=1S/C27H28O14/c1-8-20(33)23(36)26(41-27-24(37)22(35)19(32)9(2)39-27)25(38-8)18-14(31)7-16-17(21(18)34)13(30)6-15(40-16)10-3-4-11(28)12(29)5-10/h3-9,19,22-29,31-32,34-37H,1-2H3/t8?,9?,19-,22-,23-,24?,25+,26?,27-/m0/s1 |
InChI Key | GKLSYIMLZDYQBJ-WUTVGRBJSA-N |
Popularity | 25 references in papers |
Molecular Formula | C27H28O14 |
Molecular Weight | 576.50 g/mol |
Exact Mass | 576.14790556 g/mol |
Topological Polar Surface Area (TPSA) | 233.00 Ų |
XlogP | -0.30 |
Atomic LogP (AlogP) | -0.12 |
H-Bond Acceptor | 14 |
H-Bond Donor | 8 |
Rotatable Bonds | 4 |
SCHEMBL196938 |
LMPK12110512 |
Target | Value | Probability (raw) | Probability (%) |
---|---|---|---|
Human Intestinal Absorption | + | 0.7155 | 71.55% |
Caco-2 | - | 0.8931 | 89.31% |
Blood Brain Barrier | - | 0.9000 | 90.00% |
Human oral bioavailability | - | 0.7571 | 75.71% |
Subcellular localzation | Mitochondria | 0.7198 | 71.98% |
OATP2B1 inhibitior | - | 0.5619 | 56.19% |
OATP1B1 inhibitior | + | 0.8985 | 89.85% |
OATP1B3 inhibitior | + | 0.9360 | 93.60% |
MATE1 inhibitior | - | 0.8200 | 82.00% |
OCT2 inhibitior | - | 0.9000 | 90.00% |
BSEP inhibitior | + | 0.7756 | 77.56% |
P-glycoprotein inhibitior | - | 0.5742 | 57.42% |
P-glycoprotein substrate | - | 0.5373 | 53.73% |
CYP3A4 substrate | + | 0.6502 | 65.02% |
CYP2C9 substrate | - | 1.0000 | 100.00% |
CYP2D6 substrate | - | 0.8669 | 86.69% |
CYP3A4 inhibition | - | 0.8092 | 80.92% |
CYP2C9 inhibition | - | 0.8456 | 84.56% |
CYP2C19 inhibition | - | 0.9033 | 90.33% |
CYP2D6 inhibition | - | 0.9601 | 96.01% |
CYP1A2 inhibition | - | 0.8248 | 82.48% |
CYP2C8 inhibition | + | 0.7732 | 77.32% |
CYP inhibitory promiscuity | - | 0.7646 | 76.46% |
UGT catelyzed | + | 0.7000 | 70.00% |
Carcinogenicity (binary) | - | 1.0000 | 100.00% |
Carcinogenicity (trinary) | Non-required | 0.6520 | 65.20% |
Eye corrosion | - | 0.9908 | 99.08% |
Eye irritation | - | 0.9049 | 90.49% |
Skin irritation | - | 0.7203 | 72.03% |
Skin corrosion | - | 0.9297 | 92.97% |
Ames mutagenesis | + | 0.6363 | 63.63% |
Human Ether-a-go-go-Related Gene inhibition | - | 0.3905 | 39.05% |
Micronuclear | + | 0.9100 | 91.00% |
Hepatotoxicity | - | 0.7125 | 71.25% |
skin sensitisation | - | 0.9162 | 91.62% |
Respiratory toxicity | + | 0.6000 | 60.00% |
Reproductive toxicity | + | 0.7333 | 73.33% |
Mitochondrial toxicity | + | 0.6375 | 63.75% |
Nephrotoxicity | - | 0.9423 | 94.23% |
Acute Oral Toxicity (c) | III | 0.5136 | 51.36% |
Estrogen receptor binding | + | 0.8267 | 82.67% |
Androgen receptor binding | + | 0.7613 | 76.13% |
Thyroid receptor binding | + | 0.6012 | 60.12% |
Glucocorticoid receptor binding | + | 0.7263 | 72.63% |
Aromatase binding | + | 0.5368 | 53.68% |
PPAR gamma | + | 0.7416 | 74.16% |
Honey bee toxicity | - | 0.6100 | 61.00% |
Biodegradation | - | 0.8500 | 85.00% |
Crustacea aquatic toxicity | + | 0.6200 | 62.00% |
Fish aquatic toxicity | + | 0.9691 | 96.91% |
Proven Targets:
CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
---|---|---|---|---|---|
No proven targets yet! |
Predicted Targets (via Super-PRED):
CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
---|---|---|---|---|
CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 99.63% | 91.11% |
CHEMBL1951 | P21397 | Monoamine oxidase A | 99.52% | 91.49% |
CHEMBL2581 | P07339 | Cathepsin D | 98.01% | 98.95% |
CHEMBL1806 | P11388 | DNA topoisomerase II alpha | 97.49% | 89.00% |
CHEMBL1293255 | P15428 | 15-hydroxyprostaglandin dehydrogenase [NAD+] | 94.92% | 83.57% |
CHEMBL2635 | P51452 | Dual specificity protein phosphatase 3 | 94.81% | 94.00% |
CHEMBL4261 | Q16665 | Hypoxia-inducible factor 1 alpha | 92.67% | 85.14% |
CHEMBL1860 | P10827 | Thyroid hormone receptor alpha | 91.91% | 99.15% |
CHEMBL3108638 | O15164 | Transcription intermediary factor 1-alpha | 91.41% | 95.56% |
CHEMBL1293249 | Q13887 | Kruppel-like factor 5 | 90.12% | 86.33% |
CHEMBL3714130 | P46095 | G-protein coupled receptor 6 | 89.47% | 97.36% |
CHEMBL3401 | O75469 | Pregnane X receptor | 86.25% | 94.73% |
CHEMBL3475 | P05121 | Plasminogen activator inhibitor-1 | 86.04% | 83.00% |
CHEMBL5845 | P23415 | Glycine receptor subunit alpha-1 | 85.15% | 90.71% |
CHEMBL3038477 | P67870 | Casein kinase II alpha/beta | 83.80% | 99.23% |
CHEMBL1293277 | O15118 | Niemann-Pick C1 protein | 81.40% | 81.11% |
CHEMBL3194 | P02766 | Transthyretin | 80.86% | 90.71% |
CHEMBL5608 | Q16288 | NT-3 growth factor receptor | 80.65% | 95.89% |